New perspectives in the treatment of non-small cell lung cancer (NSCLC);Neue perspektiven in der behandlung des nicht kleinzelligen lungenkarzinoms (NSCLC)

Onkologie

Volumn 29, Issue SUPPL. 2, 2006, Pages 25-28

  Brockmöller, Jürgen ^a   Junker, Klaus ^b   Multhoff, Gabriele ^c  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b KLINIKUM BREMEN MITTE   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

DNA microarray technology; HSP70; Immunotherapy; NSCLC

Indexed keywords

ANTIGEN; CODEINE; CYTOCHROME P450 2D6; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GLUCURONOSYLTRANSFERASE 1A1; HEAT SHOCK PROTEIN 70; IRINOTECAN; MOLECULAR MARKER; TOLL LIKE RECEPTOR 9; TRAMADOL; TRASTUZUMAB;

DNA MICROARRAY; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HUMAN; IMMUNOTHERAPY; LUNG NON SMALL CELL CANCER; PHARMACOGENOMICS; PROGNOSIS; REVIEW; RISK FACTOR; WORLD HEALTH ORGANIZATION;

CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION PROFILING; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; NEOPLASM PROTEINS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TUMOR MARKERS, BIOLOGICAL;

EID: 33748750241     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094952     Document Type: Review

References (21)

1. Brockmöller J, et al: Molecular genetics of cancer susceptibility. Pharmacology 2000;61:212-227.
2. Innocenti, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-1388.
3. Wojnowski, et al: NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:3754-3762.
4. Kaiser, et al: Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002;20:2805-2811.
5. Tsao MS, et al: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-144.
6. Giacconne G, et al: Gefitninib in combination with gemcitabine and cisplatin in advanced NSCLC: a phase III trial - INTACT 1. J Clin Oncol 2004;22:777-784.
7. Atanackovic D, et al: Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004;172:3289-3296.
8. Tomita M, et al: Serum CEA level in pN1 non-small lung cell carcinoma patients. Anticancer Res 2005;25:3601-3605.
9. Murray N, et al: BLP25 liposome vaccine a MUC-1 vaccine for the treatment of NSCLC. Program and abstract of the Chemotherapy Found Symp XXIII: Innovative Cancer Therapy for Tomorrow. Nov 2005, New York, NY, USA.
10. Schmidt C: Immune system's Toll-like receptors have a good opportunity for cancer treatment. J Natl Cancer Inst 2006;98:574-575.
11. Binder RJ, et al: CD91 a receptor for heat shock protein gp96. Nat Immunol 2000;1:151-155.
12. Multhoff G, Botzler C, Wiesnet M, Müller E, Meier T, Wilmanns W, Issels RD: A stress-inducible 72 kDa heat shock protein is expressed on the cell surface of human tumor cells but not on normal cells. Int J Cancer 1995;61:272-279.
13. Multhoff G, et al: CD3 negative large granular lymphocytes recognize a heat inducible immunogenic determinant associated with the 72 kDa heat shock protein on human sarcoma cells. Blood 1995;86:1374-1382.
14. Multhoff G, Botzler C, Jennen L, Schmidt J, Ellwart J, Issels RD. Heat shock protein cell surface expression on colon carcinoma cells correlates with the sensitivity to lysis mediated by NK cells. J Immunol 1997;158:4341-4350.
15. Multhoff G, et al: A 14-mer Hsp70 peptide stimulates NK cell activity. Cell Stress Chaperones 2000;6:337-344.
16. Botzler C, et al: Hsp72 cell surface expression on human lung carcinoma cells is associated with an increased sensitivity to lysis by adherent NK cells. Cancer Immunol Immunother 1996;43:226-230.
17. Botzler C, et al: Definition of extracellular localized epitopes involved in an NK mediated immune response. Cell Stress Chaperones 1998;3:6-11.
18. Gehrmann M, et al: Membrane-bound Hsp70 in acute myeloid leukemia: a tumor specific recognition structure for NK cells. Haematologica 2003;88:473-475.
19. Gehrmann M, et al: Differential upregulation of cytosolic and membrane-bound heat shock protein 70 in tumor cells by anti-inflammatory drugs. Clin Cancer Res 2004;10:3354-3364.
20. Gastpar R, et al: Soluble Hsp70-peptide induces both, migration and cytolytic activity in CD3-CD94+CD56+ NK cells. J Immunol 2004;172:972-980.
21. Stangl S, et al: Control of metastasized pancreatic carcinomas in SCID/beige mice with human TKD-activated NK cells. J Immunol 2006;176:6270-6276.